Filing summary: Cerulean Pharma Inc. (not Dare Bioscience, Inc.)
Entity discrepancy: The supplied filing is Cerulean Pharma Inc.’s Form 10-Q for the quarter ended March 31, 2016, filed May 2, 2016. It does not identify Dare Bioscience, Inc. as the registrant; verify that this is the intended filing.
Business context and reporting period
Cerulean was a clinical-stage oncology company developing nanoparticle-drug conjugates. Its lead candidates were CRLX101, in Phase 2 development, and CRLX301, in Phase 1/2a. The company had no product sales and had not completed development of a product candidate.
Financial performance and liquidity
| Metric | Q1 2016 | Q1 2015 / prior date |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $9.770 million | $5.021 million |
| General and administrative expense | $3.118 million | $2.681 million |
| Operating loss | $12.888 million | $7.702 million |
| Net loss | $13.542 million | $8.428 million |
| Basic and diluted loss per share | $0.49 | $0.41 |
| Cash and cash equivalents | $60.515 million | $75.908 million at Dec. 31, 2015 |
| Operating cash used | $13.260 million | $7.941 million |
| Loan payable on balance sheet | $18.519 million carrying value | $20.324 million at Dec. 31, 2015 |
Gross margin is not applicable given the absence of revenue. Cash declined by $15.393 million during the quarter. Investing activities used $0.242 million, while financing activities used $1.891 million, primarily for loan payments. Accumulated deficit was $174.9 million. Current assets were $62.101 million versus current liabilities of $15.581 million.
Changes versus the prior comparable period
- Net loss increased 61%; operating expenses rose 67% year over year.
- R&D expense increased 95%, principally from CRLX101 manufacturing and clinical-trial costs; CRLX301 spending also rose as its trial and supporting work advanced.
- Operating cash use increased 67%. Q1 2015 financing had included $15 million of Hercules loan proceeds; Q1 2016 had no new loan proceeds and included $1.932 million of loan repayments.
- Weighted-average shares rose to 27.36 million from 20.35 million, contributing to the higher per-share loss alongside the larger net loss.
Outlook, commentary, risks and unusual items
- Management said March 31 cash was expected to fund operating expenses, debt service and capital expenditures into the second quarter of 2017. The notes separately say cash would fund needs for at least 12 months from the filing date; these runway statements should be reconciled. Management cautioned that estimates rely on assumptions and cash could be used sooner.
- The company expected significant and increasing expenses and operating losses for several years and anticipated needing additional capital. Equity financing could dilute shareholders; debt or partnerships could impose restrictions or require the company to surrender rights.
- Cerulean expected top-line data from its completed-enrollment Phase 2 RCC trial in Q3 2016. In April 2016, it reported a recommended Phase 2 dose for the CRLX101/paclitaxel ovarian-cancer combination.
- CRLX101 had previously failed to meet its primary overall-survival endpoint in a Phase 2 NSCLC study. Later-stage efficacy and safety remained uncertain; trial delays, enrollment, regulatory requirements, competition and dependence on collaborators and contract manufacturers were material risks.
- The company reported a 2015 CRLX101 drug-substance manufacturing failure requiring a replacement batch. Its Calando licensor was in Chapter 7 bankruptcy; the trustee’s next deadline concerning the license agreements was August 11, 2016.
- The Hercules loan matured July 1, 2018, carried a floating rate with a 7.30% floor, and was secured by substantially all assets other than intellectual property. The company had lost eligibility for an additional tranche of up to $5 million after not meeting a clinical-trial condition.
- The filing gives differing debt figures: $19.1 million outstanding under the loan in the notes, approximately $20.6 million in a risk-factor discussion, and $18.519 million net carrying value on the balance sheet. Confirm the applicable principal, accrued charges and carrying-value reconciliation.
- Management said disclosure controls were effective at the reasonable-assurance level; no material change in internal control over financial reporting was reported. No off-balance-sheet arrangements were reported.
Most important facts to verify
- Confirm whether the intended issuer is Cerulean Pharma or Dare Bioscience.
- Reconcile the stated cash runway and the conflicting loan balances.
- Check subsequent results and implications of the Q3 2016 RCC trial readout and the CRLX101 combination program.
- Verify the status and outcome of the Calando bankruptcy-related license deadline and CRLX101 manufacturing supply.
- Assess the amount and terms of additional financing needed, including dilution and Hercules covenant or collateral implications.